Efficacy and safety of the biosimilar denosumab candidate (Arylia) compared to the reference product (Prolia®) in postmenopausal osteoporosis: a phase III, randomized, two-armed, double-blind, parallel, active-controlled, and noninferiority clinical trial

BACKGROUND/OBJECTIVE: Osteoporosis is a global health concern with an increasing prevalence worldwide. Denosumab is an antiresoptive agent that has been demonstrated to be effective and safe in osteoporotic patients. This study aimed to compare the efficacy and safety of the biosimilar denosumab can...

Descripción completa

Detalles Bibliográficos
Autores principales: Jamshidi, Ahmadreza, Vojdanian, Mahdi, Soroush, Mohsen, Akbarian, Mahmoud, Aghaei, Mehrdad, Hajiabbasi, Asghar, Mirfeizi, Zahra, Khabbazi, Alireza, Alishiri, Gholamhosein, Haghighi, Anousheh, Salimzadeh, Ahmad, Karimzadeh, Hadi, Shirani, Fatemeh, Fard, Mohammad Reza Hatef, Nazarinia, MohammadAli, Soroosh, Soosan, Anjidani, Nassim, Gharibdoost, Farhad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9245232/
https://www.ncbi.nlm.nih.gov/pubmed/35773713
http://dx.doi.org/10.1186/s13075-022-02840-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9245232/
https://www.ncbi.nlm.nih.gov/pubmed/35773713
http://dx.doi.org/10.1186/s13075-022-02840-8

Ejemplares similares